1 Jemal A, Bray F, Center M M, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61: 69-90
[2]
2 Vogelstein B, Papadopoulos N, Velculescu V E, et al. Cancer genome landscapes. Science, 2013, 339: 1546-1558
[3]
3 Garraway L A, Lander E S. Lessons from the cancer genome. Cell, 2013, 153: 17-37
[4]
4 Huang J, Sheng H H, Shen T, et al. Correlation between genomic DNA copy number alterations and transcriptional expression in hepatitis B virus-associated hepatocellular carcinoma. FEBS Lett, 2006, 580: 3571-3581
[5]
5 Schlaeger C, Longerich T, Schiller C, et al. Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology, 2008, 47: 511-520
[6]
6 Chochi Y, Kawauchi S, Nakao M, et al. A copy number gain of the 6p arm is linked with advanced hepatocellular carcinoma: an array-based comparative genomic hybridization study. J Pathol, 2009, 217: 677-684
[7]
7 Aleksic K, Lackner C, Geigl J B, et al. Evolution of genomic instability in diethylnitrosamine-induced hepatocarcinogenesis in mice. Hepatology, 2011, 53: 895-904
[8]
8 Ding J, Huang S, Wu S, et al. Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat Cell Biol, 2010, 12: 390-399
[9]
9 Cheng N, Li Y, Han Z G. Argonaute2 promotes tumor metastasis by way of up-regulating focal adhesion kinase expression in hepatocellular carcinoma. Hepatology, 2013, 57: 1906-1918
[10]
10 Zender L, Spector M S, Xue W, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell, 2006, 125: 1253-1267
[11]
11 Sawey E T, Chanrion M, Cai C, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell, 2011, 19: 347-358
[12]
12 Keng V W, Villanueva A, Chiang D Y, et al. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol, 2009, 27: 264-274
[13]
13 Hussain S P, Schwank J, Staib F, et al. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene, 2007, 26: 2166-2176
[14]
14 Miyoshi Y, Iwao K, Nagasawa Y, et al. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res, 1998, 58: 2524-2527
[15]
15 de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA, 1998, 95: 8847-8851
[16]
16 Park W S, Dong S M, Kim S Y, et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res, 1999, 59: 307-310
[17]
17 Hanahan D, Weinberg R A. Hallmarks of cancer: the next generation. Cell, 2011, 144: 646-674
[18]
18 Li M, Zhao H, Zhang X, et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet, 2011, 43: 828-829
[19]
19 Huang J, Deng Q, Wang Q, et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet, 2012, 44: 1117-1121
[20]
20 Baylin S B, Ohm J E. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer, 2006, 6: 107-116
[21]
21 Esteller M. Epigenetics in cancer. N Engl J Med, 2008, 358: 1148-1159
[22]
22 Huang J, Zheng D L, Qin F S, et al. Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling. J Clin Invest, 2010, 120: 223-241
[23]
23 Sudo T, Utsunomiya T, Mimori K, et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer, 2005, 92: 1754-1758
[24]
24 Cheng A S, Lau S S, Chen Y, et al. EZH2-mediated concordant repression of Wnt antagonists promotes beta-catenin-dependent hepatocarcinogenesis. Cancer Res, 2011, 71: 4028-4039
[25]
25 Boyault S, Rickman D S, de Reyniès A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology, 2007, 45: 42-52
[26]
26 Lee J S, Chu I S, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology, 2004, 40: 667-676
[27]
27 Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med, 2009, 361: 1437-1447
